Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

7/23/24 8:23:56 AM ET

$CHRS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CHRS alert in real time by email

SC 13G/A 1 d796821dsc13ga.htm SC 13G/A SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

Coherus BioSciences, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

19249H103

(CUSIP Number)

July 17, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☑

Rule 13d-1(c)

☐

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 19249H103		Page 2 of 9


1	NAMES OF REPORTING PERSONS Temasek Holdings (Private) Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 5,536,949
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 5,536,949
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,536,949
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.8%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 114,725,740 shares of the Issuer’s common stock outstanding as of April 30, 2024, as set forth in the Issuer’s (as defined herein) quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on May 9, 2024.


CUSIP No. 19249H103		Page 3 of 9


1	NAMES OF REPORTING PERSONS Fullerton Management Pte Ltd
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 5,536,949
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 5,536,949
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,536,949
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.8%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 114,725,740 shares of the Issuer’s common stock outstanding as of April 30, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on May 9, 2024.


CUSIP No. 19249H103		Page 4 of 9


1	NAMES OF REPORTING PERSONS Temasek Life Sciences Private Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 5,536,949
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 5,536,949
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,536,949
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.8%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

⁽¹⁾	Based on 114,725,740 shares of the Issuer’s common stock outstanding as of April 30, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on May 9, 2024.


CUSIP No. 19249H103		Page 5 of 9


1	NAMES OF REPORTING PERSONS V-Sciences Investments Pte Ltd
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 5,536,949
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 5,536,949
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,536,949
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.8%⁽¹⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

⁽¹⁾	Based on 114,725,740 shares of the Issuer’s common stock outstanding as of April 30, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on May 9, 2024.


CUSIP No. 19249H103		Page 6 of 9

Item 1(a).

Name of Issuer:

Coherus BioSciences, Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065

Item 2(a).

Name of Person Filing:

(i)

Temasek Holdings (Private) Limited (“Temasek”);

(ii)

Fullerton Management Pte Ltd (“FMPL”);

(iii)

Temasek Life Sciences Private Limited (“TLS”); and

(iv)

V-Sciences Investments Pte Ltd (“V-Sciences” and, together with Temasek, FMPL and TLS, the “Reporting Persons”)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address of the principal business office of each Reporting Person is 60B Orchard Road, #06-18, The Atrium@Orchard, Singapore 238891.

Item 2(c).

Citizenship:

The citizenship of each of the Reporting Persons is the Republic of Singapore.

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.0001 per share (“Common Stock”).

Item 2(e).

CUSIP Number:

19249H103

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

As of July 22, 2024, V-Sciences directly owned 5,536,949 shares of the Issuer’s Common Stock. V-Sciences is a wholly-owned subsidiary of TLS, which is a wholly-owned subsidiary of FMPL, which is a wholly-owned subsidiary of Temasek. Each of TLS, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.

(b)

Percent of class:

As of July 22, 2024: 4.8%

The percentage above is based on 114,725,740 shares of the Issuer’s Common Stock outstanding as of April 30, 2024, as set forth in the Issuer’s quarterly report on Form 10-Q filed with the Commission on May 9, 2024.

(c)

Number of shares as to which the person has:

With respect to the shared power to vote, or to direct the vote, and to dispose, or to direct the disposition of, the shares of the Issuer’s Common Stock, please see Item 4(a) above regarding qualifications as to beneficial ownership.

As of July 22, 2024:

(i)

Sole power to vote or to direct the vote:


CUSIP No. 19249H103		Page 7 of 9

(ii)

Shared power to vote or to direct the vote:

5,536,949.

(iii)

Sole power to dispose or to direct the disposition of:

(iv)

Shared power to dispose or to direct the disposition of:

5,536,949.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not Applicable.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

Item 9.

Notice of Dissolution of Group.

Not Applicable.

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


CUSIP No. 19249H103		Page 8 of 9

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated: July 23, 2024	TEMASEK HOLDINGS (PRIVATE) LIMITED

	By:	/s/ Jason Norman Lee
		Name	:	Jason Norman Lee
		Title	:	Authorized Signatory

Dated: July 23, 2024	FULLERTON MANAGEMENT PTE LTD

	By:	/s/ Gregory Tan
		Name	:	Gregory Tan
		Title	:	Director

Dated: July 23, 2024	TEMASEK LIFE SCIENCES PRIVATE LIMITED

	By:	/s/ Lim Siew Lee Sherlyn
		Name	:	Lim Siew Lee Sherlyn
		Title	:	Director

Dated: July 23, 2024	V-SCIENCES INVESTMENTS PTE LTD

	By:	/s/ Khoo Ken Hui
		Name	:	Khoo Ken Hui
		Title	:	Director


CUSIP No. 19249H103		Page 9 of 9

LIST OF EXHIBITS


Exhibit No.		Description

99.1		Joint Filing Agreement, dated as of May 22, 2024, by and among Temasek, FMPL, TLS and V-Sciences (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed on May 22, 2024).

Get the next $CHRS alert in real time by email

Date	Price Target	Rating	Analyst
8/16/2024	$4.00 → $1.50	Buy → Neutral	UBS
11/17/2023	$11.00	Outperform	Robert W. Baird
11/8/2023		Buy → Hold	Maxim Group
7/24/2023	$12.00	Buy	Citigroup
5/1/2023	$24.00	Buy	Truist
3/28/2023	$11.00	Neutral → Buy	UBS
6/14/2022	$7.00	Neutral	UBS
3/7/2022	$15.00	Overweight → Neutral	JP Morgan

Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

Chat with this insight

Recent Analyst Ratings for $CHRS

$CHRS Press Releases

Fastest customizable press release news feed in the world

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

$CHRS SEC Filings

SEC Form 10-Q filed by Coherus BioSciences Inc.

Coherus BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Coherus BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure

$CHRS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

$CHRS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$CHRS Leadership Updates

Live Leadership Updates

$CHRS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form SC 13G filed by Coherus BioSciences Inc.